Oliceridine Eligible Severe Acute Pain Therapeutics
1. Olinvyk patent expiration
Treatment: Management of acute pain by intravenous injection
OLINVYK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11931350 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(6 years from now) | |
| US8835488 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(6 years from now) | |
| US9309234 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(6 years from now) | |
| US11077098 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9642842 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 30, 2025 |
Drugs and Companies using OLICERIDINE ingredient
NCE-1 date: 30 October, 2024
Market Authorisation Date: 30 October, 2020
Dosage: SOLUTION
More Information on Dosage
OLINVYK family patents
